KRYS
Krystal Biotech, Inc.
One of the first gene-therapy companies to reach patients, it makes VYJUVEK, a gel applied to open wounds that treats dystrophic epidermolysis bullosa (DEB), a rare disease where skin blisters like butterfly wings. Founded in 2016 by husband-and-wife team Krish and Suma Krishnan, who self-funded its start, the company named itself "Krystal" for the clarity and precision it wanted in gene therapy.
CUSIP: 501147102HealthcareUS1 holder
Recent Activity
2026Q2
2 buys
+8.1K shares(+17.5%)
+8.1K shares(+17.5%)
+124 shares(+1.0%)
+124 shares(+1.0%)
2026Q1
2 buys
+36.4K shares(+363.0%)
+36.4K shares(+363.0%)
+47 shares(+0.4%)
+47 shares(+0.4%)
Loading more activity...